Chemotherapy Clinical Trials offered for Acute Myelogenous Leukemia
Drug Therapy in the Treatment of Acute Myelogenous Leukemia or Myelodysplasia
This trial is for patients with AML or MDS, ages 18 and older, who have
already received bone marrow transplantation treatment and/or chemotherapy,
but
who have a higher risk of relapsing. Patients will have the opportunity
to take the investigational drug Zarnestra. This trial is overseen by
the Mayo Clinic and located in Rochester, MN. READ MORE
Drug Therapy for the Treatment of Acute Myeloid Leukemia (AML)
This trial will test the drug CEP-701 and its effects on Acute Myeloid Leukemia
(AML). After initial cycles of chemotherapy certain patients will be randomly
selected to take CEP-701. This trial is overseen by the Mayo Clinic and
located in Rochester, MN, Jacksonville, FA, Scottsdale, AZ, and Phoenix,
AZ. READ MORE
Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination with
EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia
(AML).
AML patients who are at least 18 years old may participate in a drup therapy
test that blocks certain proteins in the body that may lead to cancer like
AML. This trial is located in CA and TX. READ MORE
A Prospective Randomized Phase I/II Study of Clofarabine and Ara-C
vs Clofarabine and Idarubicin vs Clofarabine plus Idarubicin and Ara-C
in Patients with
First Relapse or First Salvage of Primary Refractory acute myeloid leukemia
(AML); and High-Grade Myelodysplastic Syndrome (MDS) (>/= 10% Blasts);
or with Chronic Myeloid Leukemia (CML) in Myeloid Blasts Phase as Front Line
Therapy or in First Salvage Chromosome Positive Chronic Myeloid Leukemia).
AML patients who are 18 years and older will be able to participate in one
of two chemotherapy drug combinations to treat AML to find the best doses
for each new drug. This trial is located at the MD Anderson Cancer Center
in Houston, TX. READ MORE
Phase I Study of Rebeccamycin Analogue (XL119) in Patients With Relapsed
or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic
Leukemia, or Chronic Myelogenous Leukemia in Blastic Phase.
This trial is investigating the best dose and effectiveness of a new chemotherapy
drug called rebeccamycin for AML patients that are at least 18 years old.
This trial is found at the MD Anderson Cancer Center in Houston, TX. READ
MORE
Phase II Study of CCI-779 in Patients With Relapsed or Refractory Acute
Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes,
or Chronic Myelogenous Leukemia in Blastic Phase.
AML patients that are at least 18 may be able to participate in a new chemotherapy
treatment in order to see how well CCI-779 works to combat AML. This trial
is located at the MD Anderson Cancer Center in Houston, TX. READ MORE
Phase I Study of Pravastatin, Idarubicin, and High-Dose Cytarabine in Patients
With Acute Myeloid Leukemia.
A new chemotherapy drug will be administered along with other high-doses
of common chemotherapy drugs to investigate the new drug’s best dose
and side effects for AML patients who are at least 18. This trial is located
in TX and WA. READ MORE
Ph I/II Study of PTK 787 (vatalanib) and Gleevec (imatinib) in Patients
with Refractory Acute Myelogenous Leukemia (AML), Agnogenic Myeloid Metaplasia
(AMM), and Chronic Myelogenous Leukemia- blastic phase (CML-BP).
AML patients who are at least 15 years old may participate in an investigation
of the best dose and side effects for two new chemotherapy drugs for treating
AML. This trial is located at the MD Anderson Cancer Center in Houston, TX.
READ
MORE
Randomized Phase II Study of Clofarabine alone versus Clofarabine
in Combination with Low-Dose Cytarabine in Previously Untreated Patients >=
60 Years with AML and High-Risk MDS.
This trial is exploring the effectiveness of combining two common chemotherapy
drugs to find a better treatment plan for AML patients who are at least 60
years old. This trial is located at the MD Anderson Cancer Center in Houston,
TX. READ MORE
Phase I Study of XK469R in Patients With Refractory Hematologic Malignancies.
This trial is investigating the effectiveness of a new chemotherapy drug
XK469R when used to treat AML patients who are at least 18 years old. This
trial is located in IL and TX. READ MORE
Phase I/II Study of RAD001 in Patients with Relapsed or Refractory Acute
Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in
Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia,
T-Cell Leukemia, or Mantle Cell Lymphoma.
Any AML patient is eligible for this trial. The trial is investigating how
effective the new drug RAD001 is for treating AML and other leukemias. This
trial is located at the MD Anderson Cancer Center in Houston, TX. READ MORE
A Phase I/II Study of Pixantrone (BBR 2778) in Patients with Refractory
Acute Myelogenous Leukemia (AML).
This trial is for AML patient who are at least 18 and is investigating the
proper dosage and infusion rate for a new chemotherapy drug that will be
used to treat AML. This trial is located at the MD Anderson Cancer Center
in Houston, TX. READ MORE
Phase I/II Study of Salvage Therapy Comprising Homoharringtonine in Patients
With Refractory Acute Promyelocytic Leukemia.
AML patients who are at least 12 years old are eligible to receive a new
experimental chemotherapy drug for AML and its subtypes. This trial is located
at the MD Anderson Cancer Center in Houston, Texas. READ MORE
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence
With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia
(AML) Expressing FLT-3 Activating Mutations.
AML patients who are at least 18 may participate in a new drug therapy program
for specific cases of AML. This trial is located in AZ, CA, FL, IL, IN, LA,
MD, MA, MI, MN, NE, NY, NC, OH, PA, SC, and TX. READ MORE
Phase III Randomized
Study of Concurrent Tretinion and Chemotherapy with or without Arsenic
Trioxide (NSC # 706363) as Initial Consolidation Therapy
Followed by Intermittent Tretinoin Maintenance Therapy Versus Observation
for Patients with Untreated Acute Promyelocytic Leukemia.
This trial will focus on new chemotherapy techniques for acute promyelocytic
leukemia, a form of AML, as well as trial the basic epidemiology of APL.
This trial is located at the City of Hope National Medical Center in Duarte,
CA. READ MORE
A Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy
With or Without Arsenic Trioxide as Initial Consolidation Therapy Followed
by
Maintenance with Intermittent Tretinoin Therapy Versus Intermittent Tretinoin
Plus Mercaptopurine and Methotrexate for Patients with Untreated Promyelocytic
Leukemia.
This trial has no age restrictions. It is trialing the effects of several
different combinations of chemotherapy drugs for acute promyelocytic leukemia,
a form of AML. It is located at Stanford University Hospital in Stanford,
CA. READ MORE
A Randomized, Open-Label Phase II Study of Oral CEP-701 Administered in
Sequence with Standard Chemotherapy to Patients with Relapsed Acute Myeloid
Leukemia (AML) Expressing FLT-3 Activating Mutations.
This trial is studying how well the drug CEP-701 works along with chemotherapy
for patients with relapsed AML. It is located at Stanford University Hospital
in Stanford, CA. READ MORE
A Phase II Study of Docetaxel (Taxotere®) (NSC#
628503) in Children with Refractory Leukemias.
This trial is for patients ages 21 and younger. It is studying the effects
and best dose of docetaxel for children with AML and is located at Stanford
University Hospital in Stanford, CA. READ MORE
Phase I and Pharmacodyamic
Study of SB-715992 in Acute Leukemia
This trial is studying the effects and best dose for a new chemotherapeutic
drug SB-715992 in treating AML patients. It is located at the City of Hope
National Medical Center in Duarte, CA. READ MORE
Phase II Trial Utilizing Idarubicin in Combination with High-Dose Ara-C
for Induction Therapy for Adult Acute Myelogenous Leukemia.
This trial is for patients ages 18-60. Patients should have no previous radiation
therapy or chemotherapy, except for Hydroxyurea. The trial will try to determine
the remission rate and treatment rate required for AML in adults. This trial
is located at the City of Hope National Medical Center in Duarte, CA. READ
MORE
A Phase I Trial and Pharmacokinetics Study of Arsenic Trioxide in Pediatric
Patients with Refractory Leukemia and Lymphoma (CCG-A0003).
This trial focuses on younger leukemia and lymphoma patients in an attempt
to find a better drug therapy for resisting the growth of these cancers.
It is located at the UCLA Jonsson Comprehensive Cancer Center in Los Angeles,
CA. READ MORE
Evaluation of Single Agent Rasburicase for 5 Days Versus Sequential Treatment
with Rasburicase from Day 1 through 3 Followed by Oral Allopurinol From Day
3 Through 5 (overlap on Day 3) Versus Single Agent Oral Allopurinol for 5
Days in the Management of Plasma Uric Acid in Adult Patients with Leukemia,
Lymphoma, and Solid Tumor Malignancies at Risk for Hyperuricemia and Tumor
Lysis Syndrome.
Adult AML patients qualify for this trial and will participate in a drug
therapy trial to better understand the build up of uric acid in cancer patients.
It is located at the UCLA Jonsson Comprehensive Cancer Center in Los Angeles,
CA. READ MORE
Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia
Associated with Tumor Lysis Syndrome in Adult and Pediatric Patients with
Lymphoma/Leukemia/Solid Tumor Malignancies at their First Relapse or Refractory
Disease.
This trial is for child AML patients and is studying the effects of a particular
drug therapy on the uric acid levels of patients with leukemias like AML.
It is located at the UCLA Jonsson Comprehensive Cancer Center in Los Angeles,
CA. READ MORE
A Phase IB, Open-Label Study to Determine the Safety and Pharmacokinetics
of Twice Daily Oral Dosing of PKC412 Administered in Combination Sequentially
and Concomitantly with Daunorubicin and Cytarabine for Standard Induction
Therapy, and High Dose Cytarabine for Consolidation in Patients with Acute
Myeloid Leukemia.
This trial is studying a new experimental drug’s effectiveness for
treating newly diagnosed AML patients who are between the ages of 18 and
60. It is located at the UCLA Jonsson Comprehensive Cancer Center in Los
Angeles, CA. READ MORE
An Open-Label, Randomized Phase II Trial of PKC412 Monotherapy in Patients
with Acute Myeloid Leukemia (AML) and Patients with High Risk Myelodysplastic
Syndrome (MDS) with either Wild Type or Mutated FLT3
This trial is studying the effectiveness of PKC412 drug therapy for AML patients
who are at least 18 years old. In addition, the trial will study bone marrow
and blood samples from AML patients to understand who will respond the best
to the PKC412 treatment plan. It is located at the UCLA Jonsson Comprehensive
Cancer Center in Los Angeles, CA. READ MORE
Phase II Trial of Arsenic Trioxide with Ascorbic Acid in the Treatment of
Adult Non-APL Acute Myelogenous Leukemia (AML).
This trial is for AML patients between the ages of 18 and 65 and is experimenting
with arsenic drug therapy for treating AML. It is located at the USC Norric
Comprehensive Cancer Center in Los Angeles, CA. READ MORE
An Ascending Dose Study of the Safety of CMA-676 as a Single Agent Treatment
of Pediatric Patients with Refractory or Relapsed Acute Myelogenous Leukemia.
This trial is looking for the best and safest dose of a new experimental
drug therapy procedure for AML patients. It is located at the Children’s
Hospital in Los Angeles, CA.
Phase II Study of Docetaxel in Pediatric Patients With Relapsed or Refractory
Acute Lymphoblastic or Acute Myeloid Leukemia.
This trial is for patients 21 years and under. The usefulness of the drug
docetaxel (a chemotherapy drug) for pediatric AML patients will be tested.
This trial is located in every state except AK and WY. READ MORE
Phase I Study of Decitabine in Children With Relapsed or Refractory Acute
Myeloid Leukemia or Acute Lymphoblastic Leukemia.
This trial if for children ages 21 and under. It will study the side effects
and best dose of decitabine in treating children with relapsed or refractory
AML. This trial is located in CA, DC, IN, MD, MA, MN, MS, NY, OH, OR, PA,
TN, TX, and WA. READ MORE
Phase I Study of Tipifarnib in Patients With Relapsed, Refractory, or High-Risk
Acute Myeloid Leukemia.
AML patients that are at least 18 years old are eligible. This trial will
test the effectiveness of the drug tipifarnib, which blocks specific enzymes
that help cells grow. This trial is located in California . READ MORE
Phase I Pilot Study of Intravenous Emulsified Fenretinide in Patients With
Refractory or Relapsed Hematologic Malignancies.
You must be at least 18 to participate in this trial. The best dose of intravenous
fenretinide for treating AML and other blood malignancies with be tested.
This trial is located in Duarte, Pasadena, Sacramento, and Los Angeles, CA.
READ MORE
Phase III Randomized Study of Daunorubicin and Cytarabine With or Without
Oblimersen in Older Patients With Previously Untreated Acute Myeloid Leukemia.
This trial will study the effects of different combination of chemotherapy
drugs on AML patients who are at least 60 years old. The trial is located
in AL, CA, DE, DC, FL, IL, IN, IA, KY, MD, MA, MI, MN, MO, NE, NV, NY, NJ,
NY, NC, OH, OK, PA, RI, TX, VT, VA, and WV. READ MORE
Phase II Study of Cyclosporine, Daunorubicin, and Cytarabine in Older Patients
With Previously Untreated Acute Myeloid Leukemia.
This trial is studying the effectiveness of chemotherapy drugs when used
together to treat AML for patients ages 55 and up. This trial is located
in AL, AR, CA, ID, IL, KS, LA, MI, MS, MO, MT, NY, NC, OH, SC, TN, TX, UT,
and WA. READ MORE
Phase II Study of Docetaxel in Pediatric Patients With Relapsed or Refractory
Acute Lymphoblastic or Acute Myeloid Leukemia.
This trial is studying how effective docetaxel is in treating AML patients
who are under 21 years old and in relapse. This trial is located in every
state except AK and WY. READ MORE
Phase I Study of Decitabine in Children With Relapsed or Refractory Acute
Myeloid Leukemia or Acute Lymphoblastic Leukemia.
This trial is studying how effective decitabine can be in treating patients
under 21 who have AML. This trial is located in CA, DC, IN, MD, MA, MN, MS,
NY, OH, OR, PA, TN, TX, and WA. READ MORE
Phase I Study of Temozolomide in Pediatric Patients With Refractory or Recurrent
Leukemia.
AML patients between 1 and 21 years of age are eligible to participate in a
study of the best dose and side effects of a new experimental chemotherapy
drug called Temozolomide. This trial is located in CA, DC, IN, MD, MA, MN,
MS, NY, OH, OR, PA, TN, and TX. READ MORE
Phase I Study of Bortezomib in Children With Refractory or Recurrent Leukemia.
AML patients between 1 and 21 years of age are eligible to participate in
a study of the best dose and side effects of a new chemotherapy drug called
Bortezomib. This trial is located in CA, DC, IN, MD, MA, MN, MS, NY, OH,
OR, PA, TN, TX, and WA. READ MORE
Phase II Study of Pentostatin in Patients With Refractory Chronic Graft-Versus-Host
Disease.
AML patients who are at least 18 can take part in a trial of a new cancer
drug called pentostatin that may help many different types of cancer. This
trial is located in AL, CA, DE, DC, FL, IL, IN, IA, KY, MD, MA, MI, MN, MO,
NE, NV, NH, NJ, NY, NC, OH, OK, PA, RI, VT, VA, and WV. READ MORE
A Phase I/II Study of Clofarabine & Cytosine Arabinoside Therapy
for Older Adults with Acute Myeloid Leukemia.
AML patients who are at least 60 years old may take part in an investigation
of the correct phase II dose for two chemotherapy drug used to treat AML. This
trial is located at the University of Alabama at Birmingham in Birmingham,
AL. READ MORE
Phase III Randomized Study of Daunorubicin and Cytarabine With or Without
Zosuquidar Trihydrochloride in Elderly Patients With Newly Diagnosed Acute
Myeloid Leukemia, Refractory Anemia With Excess Blasts (RAEB) in Transformation,
or High-Risk RAEB.
Patients newly diagnosed with AML who have not responded well to chemotherapy
in the past may take part in an investigation of new chemotherapy drugs and
combinations of drugs for AML treatment. This is located in IL, IN, KS, MA,
MI, MN, NJ, NY, OH, OK, PA, SD, and WI READ MORE
Phase II Study of FR901228 in Patients With Relapsed or Refractory Acute
Myeloid Leukemia.
AML patients who are at least 18 years old may participate in a trial of
a new chemotherapy drug that may help AML. This trial is located in IL and
TN. READ MORE
Phase I Study of Oblimersen, Cytarabine, and Daunorubicin in Older Patients
With Previously Untreated Acute Myeloid Leukemia.
This trial is for AML patients who are over 60 years old and is testing how
well a new combination of chemotherapy drugs works for treating AML. This
trial is located in IL and OH. READ MORE
Phase I Study of 3-AP (Triapine®) and High-Dose Cytarabine in
Patients With Advanced Hematologic Malignancies.
AML patients who are at least 18 may partake in a trial of a new chemotherapy
drug that will be administered with a high-dose of conventional chemotherapy
drug. This trial is located at the University of Chicago Cancer Research
Center in Chicago, IL. READ MORE
Phase I Study of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) and Cytarabine
in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic
Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia,
or High-Grade Myelodysplastic Syndromes.
AML patients who are at least 18 years old may take part in a trial study
of the best dose and side effects of a new chemotherapy drug used to treat
leukemias like AML. This trial can be located in MD and MN. READ MORE
Phase II Study of Flavopiridol, Cytarabine, and Mitoxantrone in Patients
With Poor-Risk Acute Leukemias.
AML patients who are at least 18 years old may join this trial to study the
effectiveness of certain chemotherapy drugs and combinations of those drugs
for treating AML. This trial is located at the Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins in Baltimore, MD. READ MORE
Phase I Study of Bryostatin 1 and Sargramostim (GM-CSF) in Patients With
Refractory Myeloid Malignancies.
AML patients who are at least 18 years old are eligible for this trial of
a new drug therapy program for patients with acute leukemias. This trial
is located at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
in Baltimore, MD. READ MORE
Phase I Study of Arsenic Trioxide, High-Dose Cytarabine, and Idarubicin
in Patients With Previously Untreated De Novo or Secondary Acute Myeloid
Leukemia.
AML patients who are between the ages of 18 and 59 may participate in this
trial, which is studying the side effects and best dose for arsenic trioxide,
a chemotherapy agent used for treating leukemias like AML. This trial is
located at the Roswell Park Cancer Institute in Buffalo, NY. READ MORE
Phase I Study of Temozolomide and VNP40101M in Patients With Relapsed or
Refractory Leukemias.
AML patients who are at least 18 years old may participate in this trial
that is studying the side effects and best dose of new chemotherapy drugs.
This trial is located at the Ireland Cancer Center at University Hospitals
of Cleveland and Case Western Reserve University in Cleveland, OH. READ MORE
Phase II Pilot Study of Fludarabine, Carboplatin, Topotecan, and Thalidomide
in Patients With Relapsed/Refractory or High-Risk Acute Myeloid Leukemia,
Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes.
AML patients who are at least 18 years old may participate in this trial
that is studying the best dose and side effects of new chemotherapy drugs
used with blood therapy drugs. This trial is located at the Ireland Cancer
Center at University Hospitals of Cleveland and Case Western Reserve University
in Cleveland, OH. READ MORE
Sources
ClinicalTrials.gov, www.clinicaltrials.gov
Center Watch—Clinical Trials Listing Service, http://www.centerwatch.com/patient/studies/cat92.html
UCLA Health Sciences, http://www.cancer.mednet
Mayo Clinic, http://clinicaltrials.mayo.edu/